Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial

Takanori Teshima,Yasushi Onishi,Koji Kato,Shuichi Taniguchi,Koichi Miyamura,Kentaro Fukushima,Jun Kato,Takayuki Ishikawa,Noriko Doki,Hirohisa Nakamae,Yoshinobu Maeda,Yoshihiro Inamoto,Masaya Okada,Akio Maki,Fumika Shimada,Takeshi Tajima,Monika Wroclawska,Robert Zeiser,Makoto Onizuka

DOI: https://doi.org/10.1007/s12185-024-03772-6

2024-05-27

International Journal of Hematology

Abstract:Acute graft-versus-host disease (aGvHD) is a major complication after allogeneic hematopoietic stem cell transplantation in Japan and other countries. Nearly one-third of patients do not respond to standard systemic steroid therapy and no standard second-line treatment has been established in Japan. We report efficacy and safety findings of ruxolitinib versus best available therapy (BAT) from a subgroup analysis of the international, phase 3 REACH2 study in Japanese patients with steroid-refractory aGvHD. The primary endpoint was overall response rate (ORR) at day 28. Overall, 9 patients received ruxolitinib and 21 received BAT. The ORR at day 28 (88.9% vs 52.4%) and durable ORR at day 56 (66.7% vs 28.6%) were higher with ruxolitinib versus BAT. The estimated cumulative incidence of loss of response at 6 months was 12.5% with ruxolitinib and 18.2% with BAT. The median failure-free survival was longer with ruxolitinib versus BAT (2.73 vs 1.25 months). The most common adverse events up to day 28 in the ruxolitinib and BAT groups were anemia (55.6% vs 19.0%) and thrombocytopenia (44.4% vs 4.8%, respectively). Ruxolitinib showed better efficacy outcomes and a consistent safety profile compared with BAT in the Japanese subgroup, and the findings were consistent with overall study results.

hematology

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the efficacy and safety of ruxolitinib compared with the best available therapy (BAT) in Japanese patients for the treatment of steroid - refractory acute graft - versus - host disease (SR - aGvHD). Specifically, the primary endpoint of the study was the overall response rate (ORR) on day 28, and the secondary endpoints included the durable overall response rate (DORR) on day 56, failure - free survival (FFS), non - relapse mortality (NRM), malignancy relapse/progression (MR), and the incidence of chronic graft - versus - host disease (cGvHD). ### Background Acute graft - versus - host disease (aGvHD) is one of the main complications after allogeneic hematopoietic stem cell transplantation (HSCT), especially in Japan and other countries. Approximately one - third of patients do not respond to standard systemic steroid treatment, and a standard second - line treatment regimen has not yet been established in Japan. The Janus kinase (JAK) signaling pathway plays an important role in regulating the development, proliferation, and activation of multiple immune cells such as dendritic cells, macrophages, T cells, B cells, and neutrophils, which are of great significance in the pathogenesis of aGvHD. Ruxolitinib is an oral selective JAK1/2 inhibitor, which has been approved by the FDA for the treatment of SR - aGvHD or chronic GvHD in adults and children. ### Research design REACH2 is an international, randomized, open - label phase III clinical trial to evaluate the efficacy and safety of ruxolitinib and BAT in patients with SR - aGvHD. The study included 309 patients with SR - aGvHD, who were randomly divided into the ruxolitinib group and the BAT group. The primary endpoint was the overall response rate on day 28, and the secondary endpoints included the durable overall response rate on day 56, etc. ### Results - **Primary endpoint**: The overall response rate on day 28 was 88.9% in the ruxolitinib group and 52.4% in the BAT group. - **Secondary endpoints**: - The durable overall response rate on day 56 was 66.7% in the ruxolitinib group and 28.6% in the BAT group. - The median failure - free survival was 2.73 months in the ruxolitinib group and 1.25 months in the BAT group. - The non - relapse mortality was lower in the ruxolitinib group. - The incidence of chronic GvHD was low in both groups. ### Safety The most common adverse events in the ruxolitinib group included anemia, thrombocytopenia, and decreased white blood cell count. Severe adverse events occurred in 66.7% and 42.9% of patients in the ruxolitinib group and the BAT group, respectively, and the most common severe adverse events were sepsis and acute kidney injury. ### Conclusion Ruxolitinib shows better efficacy and consistent safety in the treatment of SR - aGvHD in Japanese patients, which is consistent with the overall research results. This provides a new option for the treatment of SR - aGvHD and may become the standard treatment regimen in the future.

Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial

Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study

Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis

Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study

Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Ruxolitinib Combined with Dexamethasone in Adult Patients with Secondary HLH: a Single-Centre Pilot Trial

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and Safety of Ruxolitinib for Steroid-Refractory Graft-Versus-host Disease: Systematic Review and Meta-Analysis of Randomised and Non-Randomised Studies

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4)

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial

Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study

Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease

Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis

Ruxolitinib Combined with Etanercept Induce a Rapid Response to Corticosteroid-refractory Severe Acute Graft versus Host Disease after Allogeneic Stem Cell Transplantation: Results of a Multi-center Prospective Study.